Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | 2026-10-15 14:22:03 | 7.25 | -0.09 | -1.29 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGEN | 0001356090 | PRECIGEN, INC. | US74017N1054 | 549300XCWNQU35K64G19 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | VA | 20374 SENECA MEADOWS PARKWAY | GERMANTOWN | MD | 20876 | UNITED STATES | US | 301-556-9900 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | INTREXON CORP | Biotechnology | 1998-05-21 | — | 600 | http://precigen.com | 219,400,000 | 358,008,798 | 358,035,247 | Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. | 2026-10-09 02:10:11 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 219,400,000 | -20,400,000 | -8.5071 | 353,928,672 | 58,763,612 | 19.9087 |
| 2024 | 239,800,000 | 62,500,000 | 35.251 | 295,165,060 | 42,745,370 | 16.9342 |
| 2023 | 177,300,000 | 15,200,000 | 9.3769 | 252,419,690 | 224,977 | 0.0892 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Donald P. Lehr | Chief Legal Officer | 2025 | 575,000 | 0 | 408,751 | 132,249 | 46,896 | 1,430,196 |
| Rutul Shah | Chief Operating Officer | 2025 | 485,000 | 0 | 499,899 | 145,498 | 45,603 | 1,560,912 |
| Helen Sabzevari | Chief Executive Officer | 2025 | 1,000,000 | 0 | 2,215,000 | 1,049,997 | 20,132 | 5,354,329 |
| Harry Thomasian Jr. | Chief Financial Officer | 2025 | 488,000 | 0 | 464,970 | 131,758 | 35,757 | 1,494,705 |
| Phil Tennant | Chief Commercial Officer | 2025 | 510,000 | 0 | 271,103 | 137,700 | 43,853 | 1,229,956 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 47 |
| 2024 | 99 |
| 2023 | 134 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 9,684,000 | — | — |
| Cost Of Revenue | — | — | — |
| Gross Profit | 9,684,000 | — | — |
| Research And Development Expenses | 41,333,000 | — | — |
| General And Administrative Expenses | 70,128,000 | — | — |
| Operating Expenses | 120,191,000 | — | — |
| Operating Income | -110,507,000 | -128,028,000 | -96,362,000 |
| Net Income | -250,642,000 | -126,235,000 | -95,904,000 |
| Earnings Per Share Basic | -1.37 | -0.47 | -0.39 |
| Earnings Per Share Diluted | -1.37 | -0.47 | -0.39 |
| Weighted Average Shares Outstanding Basic | 312,980,562 | 267,727,426 | 244,536,221 |
| Weighted Average Shares Outstanding Diluted | 312,980,562 | 267,727,426 | 244,536,221 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 30,234,000 | 29,517,000 | 7,578,000 |
| Marketable Securities Current | 67,624,000 | 68,393,000 | 55,277,000 |
| Accounts Receivable | 3,916,000 | 926,000 | 902,000 |
| Inventories | 9,581,000 | — | — |
| Non Trade Receivables | 446,000 | 237,000 | 673,000 |
| Other Assets Current | 3,434,000 | 3,341,000 | 4,325,000 |
| Total Assets Current | 115,235,000 | 102,414,000 | 68,755,000 |
| Marketable Securities Non Current | 2,511,000 | — | — |
| Property Plant And Equipment | 13,758,000 | 13,831,000 | 7,111,000 |
| Other Assets Non Current | 908,000 | 371,000 | 767,000 |
| Total Assets Non Current | 40,270,000 | 42,852,000 | 82,288,000 |
| Total Assets | 155,505,000 | 145,266,000 | 151,043,000 |
| Accounts Payable | 11,985,000 | 3,531,000 | 1,726,000 |
| Deferred Revenue | 517,000 | 589,000 | 509,000 |
| Short Term Debt | 0 | — | 0 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 37,306,000 | 21,518,000 | 22,985,000 |
| Long Term Debt | 93,174,000 | — | — |
| Other Liabilities Non Current | 134,000 | — | — |
| Total Liabilities Non Current | 97,288,000 | 57,017,000 | 9,560,000 |
| Total Liabilities | 134,594,000 | 78,535,000 | 32,545,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -2,341,348,000 | -2,090,706,000 | -1,964,471,000 |
| Accumulated Other Comprehensive Income | 7,000 | 12,000 | -1,947,000 |
| Total Shareholders Equity | 20,911,000 | 38,513,000 | 118,498,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 3,199,000 | 4,526,000 | 6,668,000 |
| Share Based Compensation Expense | 10,866,000 | 9,471,000 | 9,888,000 |
| Other Non Cash Income Expense | 0 | 0 | -2,000 |
| Change In Accounts Receivable | 2,990,000 | 24,000 | -76,000 |
| Change In Inventories | 9,209,000 | — | — |
| Change In Non Trade Receivables | 209,000 | -438,000 | -12,153,000 |
| Change In Other Assets | 556,000 | -120,000 | -129,000 |
| Change In Accounts Payable | 8,768,000 | 1,549,000 | -2,421,000 |
| Change In Other Liabilities | 6,662,000 | 3,145,000 | 5,227,000 |
| Cash From Operating Activities | -87,831,000 | -68,173,000 | -66,930,000 |
| Purchases Of Marketable Securities | 208,006,000 | 187,206,000 | 185,026,000 |
| Sales Of Marketable Securities | 208,466,000 | 175,016,000 | 183,377,000 |
| Acquisition Of Property Plant And Equipment | 1,995,000 | 8,584,000 | 1,536,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,535,000 | -20,714,000 | -3,087,000 |
| Tax Withholding For Share Based Compensation | 1,776,000 | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | -355,000 | 31,237,000 | 72,808,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 92,818,000 | — | — |
| Repayment Of Long Term Debt | 0 | 0 | 43,219,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 90,048,000 | 110,583,000 | 29,589,000 |
| Change In Cash | 717,000 | 21,669,000 | -40,748,000 |
| Cash At End Of Period | 30,234,000 | 29,517,000 | 7,578,000 |
| Income Taxes Paid | 3,000 | 4,000 | 21,000 |
| Interest Paid | 3,510,000 | 7,000 | 1,171,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.37 | -0.47 | -0.39 |
| Price To Earnings Ratio | -3.0511 | -2.383 | -3.4359 |
| Earnings Growth Rate | 191.4894 | 20.5128 | -378.5714 |
| Price Earnings To Growth Ratio | -0.0159 | -0.1162 | 0.0091 |
| Book Value Per Share | 0.0668 | 0.2492 | 0.4846 |
| Price To Book Ratio | 62.5632 | 4.4935 | 2.7653 |
| Ebitda | -243,573,000 | -121,705,000 | -89,215,000 |
| Enterprise Value | 1,371,198,749.16 | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 4.4557 | — | — |
| Capital Expenditures | 3,126,000 | 11,246,000 | 6,450,000 |
| Free Cash Flow | -90,957,000 | -79,419,000 | -73,380,000 |
| Return On Equity | -11.9861 | -3.2777 | -0.8093 |
| One Year Beta | 1.7819 | 1.6578 | 2.1757 |
| Three Year Beta | 1.8376 | 1.8106 | 1.6677 |
| Five Year Beta | 1.6937 | 1.6063 | 1.6123 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Thomasian Harry Jr. | Chief Financial Officer | 2026-09-23 | 10,744 | A | 268,993 |
| Thomasian Harry Jr. | Chief Financial Officer | 2026-09-23 | 42,918 | A | 311,911 |
| Thomasian Harry Jr. | Chief Financial Officer | 2026-09-23 | 2 | A | 311,913 |
| Thomasian Harry Jr. | Chief Financial Officer | 2026-09-23 | 1 | A | 311,914 |
| Thomasian Harry Jr. | Chief Financial Officer | 2026-09-23 | 10,744 | D | 169,256 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Flower City Capital | 2026-09-30 | 171,200 | 20,000 | 8.56 |
| CHIRON CAPITAL MANAGEMENT, LLC | 2026-09-30 | 97,156 | 11,350 | 8.56 |
| Fortitude Family Office, LLC | 2026-09-30 | 1,216 | 142 | 8.5634 |
| Essential Partners LLC | 2026-09-30 | 60 | 7 | 8.5714 |
| True Wealth Design, LLC | 2026-09-30 | 240 | 28 | 8.5714 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 3,289 | 20,622.03 | 0.0857 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech ETF | BBP | 304,977 | 1,912,205.79 | 1.9405 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 18,246 | 114,402.42 | 0.0141 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Small Cap Stock Fund Institutional Shares | UISCX | 144,523 | 906,159.21 | 0.0944 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Small Cap Stock Fund Shares | USCAX | 144,523 | 906,159.21 | 0.0944 |